Inside the research
Bio-Techne Corporation
TECH Research profile · latest available data
Price overview
$72.61
▲ +0.04 (+0.1%)
| 52w hi | $72.61 |
|---|---|
| 52w lo | $43.17 |
| Vol | 2.18M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.29
| Short | +0.35 |
|---|---|
| Medium | +0.38 |
| Long | -0.03 |
computed 2026-09-27
Key fundamentals
Bio-Techne Corporation
Healthcare · Biotechnology
| Market cap | $11.39B |
|---|---|
| Enterprise value | $11.41B |
| Trailing P/E | 62.59x |
| Forward P/E | 31.48x |
| EV / EBITDA | 34.15x |
| P / S (ttm) | 9.37x |
| Profit margin | 15.0% |
| Return on equity | 9.0% |
| Revenue growth | +1.3% |
| Debt / equity | 13.71 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.08 | |
| Sector | +0.08 | |
| Technical | +0.26 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Risk Metrics
| Beta vs SPX | 1.10 |
|---|---|
| Corr SPX | 0.40 |
| Annual vol | 44.1% |
| Annual ret | +5.9% |
| Sharpe | 0.13 |
| Max DD | -45.8% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $62.64 |
|---|---|
| High / Low | $76.00 / $49.00 |
| Median | $65.00 |
| Analysts | 11 |
| Strong Buy | 1 | |
|---|---|---|
| Buy | 9 | |
| Hold | 4 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-07 | Wells Fargo | → Overweight |
| 2026-05-07 | Evercore ISI Group | → In-Line |
| 2026-05-07 | Citigroup | → Buy |
| 2026-04-06 | Evercore ISI Group | → In-Line |
| 2026-02-06 | Wells Fargo | → Overweight |
| 2026-02-05 | UBS | → Buy |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-12 | Earnings Release, Other Material Event… | read |
| 2026-06-26 | Material Agreement, Officer / Director Change… | read |
| 2026-06-25 | Reg FD Disclosure, Exhibits | read |
| 2026-05-06 | Earnings Release, Other Material Event… | read |
| 2026-02-11 | Officer / Director Change, Other Material Event… | read |
| 2026-02-04 | Earnings Release, Other Material Event… | read |
| 2025-11-05 | Earnings Release, Shareholder Vote… | read |
| 2025-08-06 | Earnings Release, Other Material Event… | read |
| 2025-05-07 | Earnings Release, Other Material Event… | read |
| 2025-05-06 | Reg FD Disclosure | read |
| 2025-03-04 | Officer / Director Change, Exhibits | read |
| 2025-02-05 | Earnings Release, Officer / Director Change… | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 99.8% |
| HHI | 3,772 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Fidelity / FMR LLC | $903.95M | 12.79M |
| State Street Corp | $422.51M | 5.98M |
| Capital Research / Capital World | $175.11M | 2.48M |
| Millennium Management | $79.35M | 1.12M |
| Citadel Advisors | $74.19M | 1.05M |
| Bridgewater Associates | $1.89M | 26.75K |
| AQR Capital Management | $1.75M | 24.79K |
| T. Rowe Price Group | $15.97K | 226.00K |
As of 2026-06-30
Dividends
| Yield (TTM) | 0.22% |
|---|---|
| $ / share (TTM) | $0.16 |
| 5y CAGR | +0.0% |
Annual dividend per share
| 2021 | $0.32 |
|---|---|
| 2022 | $0.32 |
| 2023 | $0.32 |
| 2024 | $0.32 |
| 2025 | $0.32 |
| 2026 | $0.08 |
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.14B | +11.9% | |
| Gross profit | $790.27M | +9.4% | |
| Operating income | $298.94M | +4.4% | |
| Net income | $73.40M | -2.8% | |
| Cash from ops | $287.56M | +8.5% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $72.59 | $72.64 | $72.56 | $72.61 | 2.18M |
| Sep 24 | $72.54 | $72.63 | $72.51 | $72.57 | 2.99M |
| Sep 23 | $72.50 | $72.64 | $72.48 | $72.52 | 3.56M |
| Sep 22 | $72.52 | $72.69 | $72.46 | $72.55 | 3.44M |
| Sep 21 | $72.50 | $72.54 | $72.44 | $72.47 | 4.67M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →